Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

'Smuggling' Drugs at the Cellular Level

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
Drexel researchers use ultrasound to deliver customized medication through the skin.

Medicated adhesive patches have become a preferred method of delivery for everything from nicotine to hormones to motion sickness medication.

Drexel University researchers are trying to expand the possibilities of this system--called transdermal delivery--with the help of a cleverly designed delivery vehicle and an ultrasonic "push," or pressure from sound waves.

The advantage of transdermal drug delivery is the ability to regulate the release of medication into the bloodstream and promote a more direct interaction of the treatment with the affected area. But the challenge of this method is that the skin is very good at protecting the body from invaders--even the helpful kind.

Molecules of nicotine and medication currently delivered via adhesive patch are small enough to pass through the pores. To sneak a slightly larger package--say, insulin or arthritis medication--past the body's epidermal defenses requires a bit more biological trickery.

Steven P. Wrenn, of Drexel's College of Engineering, and Peter A. Lewin, from Drexel's School of Biomedical Engineering, Science and Health Systems, are driving forces behind this research. Their team is investigating the molecular architecture of human skin and certain promising drugs and compounds, as well as the mechanics of an ultrasound interface necessary to broaden the capabilities of transdermal drug delivery.

Their work is part of a larger trend: More and more, researchers are exploring advanced materials and manufacturing techniques for biomedical applications. New, high-precision technologies and more rapid, personalized fabrication methods allow engineers to design on smaller scales, such as those required to traverse the human body.

The package

The Drexel team is looking at a drug called Methotrexate (MTX) as an example of the cargo that could one day be transported into the body using an ultrasound "Band-Aid." MTX is used to treat arthritis and various types of cancer. It is typically taken orally, but after prolonged use it can become toxic to the liver. This side effect could be avoided if the drug were delivered transdermally, as afflicted cells would use up much of the medication before it could reach the liver.

It's not an ideal candidate for topical application, however, because its molecules are too large to easily pass through the pores of the skin. It is also easily dissolved in water, which means that, to be effective, it must be contained and protected until it reaches its destination.

The carrier

Wrenn's group is designing a vessel that can transport the medicine and penetrate the skin's first line of defense: the stratum corneum. This barrier is the body's equivalent of a brick wall built with dead skin cell bricks and a lipid mortar.

The group selected the liposome, a fabricated lipid sac filled with water, as the carrier. Liposomes are prime candidates for the job because they are made of the same lipid substrate as the stratum corneum's "mortar," so they can pass through the skin virtually unnoticed.

The team is also engineering the sacs so they're hearty enough to survive a transdermal push, but capable of being opened to release the medicine once inside the body.

The push and the pop

After coaxing the liposomes through the epidermis, the tunable ultrasound patch would "pop" them open to deliver the medicine.

But this interaction is where the real problem lies. The liposome, while a perfect craft for making a stealthy, transdermal entry is not rugged enough to withstand the intensity of ultrasound required to push it through the skin.

Wrenn's group devised a creative solution to this quandary by adding a bit of ballast to the liposome vessel, in the form of tiny gas-filled sacs called microbubbles.

Microbubbles respond to ultrasound in two ways that are key to making the liposome's transdermal voyage a success. First, they can be pushed by ultrasound at an intensity gentle enough to keep the liposome intact. So, nesting the microbubbles inside a liposome is analogous to raising the sail on a boat to catch the wind.

Secondly, when the intensity of the ultrasound is turned up a bit, it causes microbubbles to wobble like a spring and--if the intensity is high enough--pop. Wrenn's group has shown that these gas implosions in the vicinity of the liposome can rip it open, thus allowing disbursal of its contents.

A significant advantage of their approach over current transdermal delivery methods is that it could easily be customized to work for a broad array of drugs and other biological products.

The future

By combining these findings, the team suggests that a liposome laden with a payload of medicine and using microbubbles to sail an ultrasonic "wind" should be able to traverse the epidermis and enter the body. An adjustment to the ultrasound frequency could then pop the microbubbles and split open the liposome to release the medicine.

With a hefty amount of research on liposome architecture underway, the next step for the group will be to fine-tune the ultrasound patch delivery system and work toward a successful transdermal push.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!